Scarica l'app Stockscreener
4.09
0.00%
0.00
Dopo l'orario di chiusura:
4.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCYX Giù?
Forum
Previsione
Frazionamento azionario
Scynexis Inc Borsa (SCYX) Ultime notizie
SCYNEXIS (SCYX) Holds Near Support Amid Quiet TradingFast Moving Stocks - newsline.com
SCYNEXIS Q1 2026 Earnings: EPS Misses Estimates as Company Reports No RevenueInvestor Earnings Call - newsline.com
SCYNEXIS, Inc. Hits New 52-Week High of $5.62, Up 157.49% - MarketsMojo
SCYNEXIS (SCYX) Picks Up Slightly as Stock Bounces Within Established RangeDiagonal Spread Trade - newsline.com
SCYNEXIS (SCYX) Slides 2.6% as Stock Approaches Key SupportATR Trailing Stop - newsline.com
Total liabilities of SCYNEXIS, Inc. – MUN:135 - TradingView
SCYNEXIS, Inc. Balance Sheet – MUN:135 - TradingView
Net debt of SCYNEXIS, Inc. – FWB:135 - TradingView
Pretax income of SCYNEXIS, Inc. – TRADEGATE:135 - TradingView
Free cash flow of SCYNEXIS, Inc. – FWB:135 - TradingView
SCYNEXIS, Inc. Cash Flow – MUN:135 - TradingView
SCYNEXIS, Inc. Cash Flow – FWB:135 - TradingView
Pretax income of SCYNEXIS, Inc. – GETTEX:135 - TradingView
Working capital per share of SCYNEXIS, Inc. – TRADEGATE:135 - TradingView
SCYNEXIS, Inc. Statistics – TRADEGATE:135 - TradingView
Net margin % of SCYNEXIS, Inc. – MUN:135 - TradingView
Net income of SCYNEXIS, Inc. – TRADEGATE:135 - TradingView
SCYNEXIS Inc (FRA:135) Stock Earnings Transcripts - GuruFocus
SCYNEXIS Inc (FRA:135) Stock Price & 30 Year Financial Data - GuruFocus
SCYNEXIS Inc (STU:135) Stock Price & 30 Year Financial Data - GuruFocus
Scynexis Shareholder Alert - TMX Newsfile
SCYNEXIS Inc. (SCYX) Declines 4.12%: Stock Approaches Key Support at $0.66Put Call Ratio - newsline.com
SCYNEXIS to implement 1-for-8 reverse stock split - MSN
Scynexis (SCYX) completes 1-for-8 reverse split and cuts authorized shares - Stock Titan
SCYX Q1 2026 Earnings: EPS Misses Estimates as No Revenue Reported, Stock Rises 4.91%Share Repurchase Impact - The Legal Advocate
SCYNEXIS (SCYX) Slips Over 4%: Support Level in Focus Amid Biotech Sector HeadwindsVolume Dry Up - newsline.com
SCYNEXIS (SCYX) Falls 6.88%: Key Support and Resistance Levels Under ScrutinyNews Sentiment - The Legal Advocate
Stock Market Today: S&P 500, Dow, Nasdaq Futures Up Amid US 'Defensive Strikes' On Iran— Elbit Systems, Intuitive Machines, Zscaler In Focus (UPDATED) - Benzinga
SCYX Q1 2026 Earnings: EPS Misses Estimates; Stock Rises Despite Wider-Than-Expected LossFinancial Data - The Legal Advocate
SCYNEXIS Announces One-for-Eight Reverse Stock Split - The Manila Times
SCYNEXIS (SCYX) Announces 1-for-8 Reverse Stock Split to Meet Na - GuruFocus
SCYNEXIS announces 1-for-8 reverse stock split effective May 29 - Investing.com UK
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split - TipRanks
SCYNEXIS announces 1-for-8 reverse stock split effective May 29 By Investing.com - Investing.com South Africa
Scynexis stock falls 7% on reverse stock split announcement By Investing.com - Investing.com South Africa
Scynexis stock falls 7% on reverse stock split announcement - Investing.com
SCYNEXIS (SCYX) approves 1-for-8 reverse stock split and major cut to authorized shares - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYX: Shareholders approved a reverse stock split and reduction of authorized shares - TradingView
SCYX: Reverse stock split and share reduction approved; no questions or other proposals raised - TradingView
SCYNEXIS (SCYX) Falls -7.43% — Watching $0.66 Support 2026-05-18Overbought Alert - Newser
Why did SCYX stock jump 10% in pre-market today? - MSN
Press Releases about SCYNEXIS, Inc.Common Stock - The Chronicle-Journal
CVI Investments and Heights disclose 6.2% stake in SCYNEXIS (SCYX) - Stock Titan
SCYNEXIS (SCYX) price target increased by 20.73% to 4.28 - MSN
Maxim Group Maintains Scynexis(SCYX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Financial Overview of SCYX: Cash Position Strengthened - GuruFocus
Scynexis: Q1 Earnings Snapshot - marketscreener.com
Rare-disease biotech SCYNEXIS buys kidney-drug candidate, funds runway to 2029 - Stock Titan
BRIEF-Scynexis Q1 Operating Expenses USD 16.939 Million - TradingView
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):